{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:29:59Z","timestamp":1794554999004,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Nonalcoholic fatty liver disease (NAFLD) and its evolution to inflammatory steatohepatitis (NASH) are the most common causes of chronic liver damage and transplantation that are reaching epidemic proportions due to the upraising incidence of metabolic syndrome, obesity, and diabetes. Currently, there is no approved treatment for NASH. The mitochondrial citrate carrier, Slc25a1, has been proposed to play an important role in lipid metabolism, suggesting a potential role for this protein in the pathogenesis of this disease. Here, we show that Slc25a1 inhibition with a specific inhibitor compound, CTPI-2, halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, while starkly mitigating obesity induced by a high-fat diet. These effects are differentially recapitulated by a global ablation of one copy of the\n                    <jats:italic>Slc25a1<\/jats:italic>\n                    gene or by a liver-targeted\n                    <jats:italic>Slc25a1<\/jats:italic>\n                    knockout, which unravel dose-dependent and tissue-specific functions of this protein. Mechanistically, through citrate-dependent activities, Slc25a1 inhibition rewires the lipogenic program, blunts signaling from peroxisome proliferator-activated receptor gamma, a key regulator of glucose and lipid metabolism, and inhibits the expression of gluconeogenic genes. The combination of these activities leads not only to inhibition of lipid anabolic processes, but also to a normalization of hyperglycemia and glucose intolerance as well. In summary, our data show for the first time that Slc25a1 serves as an important player in the pathogenesis of fatty liver disease and thus, provides a potentially exploitable and novel therapeutic target.\n                  <\/jats:p>","DOI":"10.1038\/s41418-020-0491-6","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T04:02:42Z","timestamp":1579492962000},"page":"2143-2157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD\/NASH"],"prefix":"10.1038","volume":"27","author":[{"given":"Mingjun","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Mosaoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1097-0962","authenticated-orcid":false,"given":"Garrett T.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kasprzyk-Pawelec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas","family":"Gadre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Parasido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Catalina-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Kallakury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Avantaggiati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"key":"491_CR1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","volume":"53","author":"Y Sumida","year":"2018","unstructured":"Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD\/NASH. J Gastroenterol. 2018;53:362\u201376.","journal-title":"J Gastroenterol"},{"key":"491_CR2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","volume":"16","author":"QM Anstee","year":"2019","unstructured":"Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411\u201328.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"491_CR3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/gutjnl-2016-312431","volume":"66","author":"Y Rotman","year":"2017","unstructured":"Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180\u201390.","journal-title":"Gut"},{"key":"491_CR4","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jhep.2015.02.041","volume":"62","author":"V Ratziu","year":"2015","unstructured":"Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62:S65\u201375.","journal-title":"J Hepatol"},{"key":"491_CR5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","volume":"26","author":"CW Kim","year":"2017","unstructured":"Kim CW, Addy C, Kusunoki J, Anderson NN, Deja S, Fu X, et al. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metab. 2017;26:394\u2013406.e6.","journal-title":"Cell Metab"},{"key":"491_CR6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cmet.2005.04.002","volume":"1","author":"MV Chakravarthy","year":"2005","unstructured":"Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, et al. \u201cNew\u201d hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab. 2005;1:309\u201322.","journal-title":"Cell Metab"},{"key":"491_CR7","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.bbamcr.2016.03.007","volume":"1863","author":"F Palmieri","year":"2016","unstructured":"Palmieri F, Monn\u00e9 M. Discoveries, metabolic roles and diseases of mitochondrial carriers: a review. Biochim Biophys Acta. 2016;1863:2362\u201378.","journal-title":"Biochim Biophys Acta"},{"key":"491_CR8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.mcn.2008.07.027","volume":"39","author":"TM Maynard","year":"2008","unstructured":"Maynard TM, Meechan DW, Dudevoir ML, Gopalakrishna D, Peters AZ, Heindel CC, et al. Mitochondrial localization and function of a subset of 22q11 deletion syndrome candidate genes. Mol Cell Neurosci. 2008;39:439\u201351.","journal-title":"Mol Cell Neurosci"},{"key":"491_CR9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10545-017-0106-7","volume":"41","author":"A Pop","year":"2018","unstructured":"Pop A, Williams M, Struys EA, Monne M, Jansen EEW, De Grassi A, et al. An overview of combined D-2- and L-2-hydroxyglutaric aciduria: functional analysis of CIC variants. J Inherit Metab Dis. 2018;41:169\u201380.","journal-title":"J Inherit Metab Dis"},{"key":"491_CR10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/8904_2014_378","volume":"19","author":"P Prasun","year":"2015","unstructured":"Prasun P, Young S, Salomons G, Werneke A, Jiang YH, Struys E, et al. Expanding the Clinical Spectrum of Mitochondrial Citrate Carrier (SLC25A1) deficiency: facial dysmorphism in siblings with epileptic encephalopathy and combined D,L-2-hydroxyglutaric aciduria. JIMD Rep. 2015;19:111\u20135.","journal-title":"JIMD Rep"},{"key":"491_CR11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JND-140021","volume":"1","author":"A Chaouch","year":"2014","unstructured":"Chaouch A, Porcelli V, Cox D, Edvardson S, Scarcia P, De Grassi A, et al. Mutations in the Mitochondrial Citrate Carrier SLC25A1 are associated with impaired neuromuscular transmission. J Neuromuscul Dis. 2014;1:75\u201390.","journal-title":"J Neuromuscul Dis"},{"key":"491_CR12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/jmedgenet-2012-101485","volume":"50","author":"S Edvardson","year":"2013","unstructured":"Edvardson S, Porcelli V, Jalas C, Soiferman D, Kellner Y, Shaag A, et al. Agenesis of corpus callosum and optic nerve hypoplasia due to mutations in SLC25A1 encoding the mitochondrial citrate transporter. J Med Genet. 2013;50:240\u20135.","journal-title":"J Med Genet"},{"key":"491_CR13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ajhg.2013.03.009","volume":"92","author":"B Nota","year":"2013","unstructured":"Nota B, Struys EA, Pop A, Jansen EE, Fernandez Ojeda MR, Kanhai WA, et al. Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria. Am J Hum Genet. 2013;92:627\u201331.","journal-title":"Am J Hum Genet"},{"key":"491_CR14","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1126\/science.290.5499.2137","volume":"290","author":"B Rogina","year":"2000","unstructured":"Rogina B, Reenan RA, Nilsen SP, Helfand SL. Extended life-span conferred by cotransporter gene mutations in Drosophila. Science. 2000;290:2137\u201340.","journal-title":"Science"},{"key":"491_CR15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fonc.2018.00170","volume":"8","author":"J Hlouschek","year":"2018","unstructured":"Hlouschek J, Hansel C, Jendrossek V, Matschke J. The Mitochondrial Citrate Carrier (SLC25A1) sustains redox homeostasis and mitochondrial metabolism supporting radioresistance of cancer cells with tolerance to cycling severe hypoxia. Front Oncol. 2018;8:170.","journal-title":"Front Oncol"},{"key":"491_CR16","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41418-018-0101-z","volume":"25","author":"HR Fernandez","year":"2018","unstructured":"Fernandez HR, Gadre SM, Tan M, Graham GT, Mosaoa R, Ongkeko MS, et al. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death Differ. 2018;25:1239\u201358.","journal-title":"Cell Death Differ"},{"key":"491_CR17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.bbagrm.2014.07.013","volume":"1839","author":"V Infantino","year":"2014","unstructured":"Infantino V, Iacobazzi V, Menga A, Avantaggiati ML, Palmieri F. A key role of the Mitochondrial Citrate Carrier (SLC25A1) in TNFalpha- and IFNgamma-triggered inflammation. Biochim Biophys Acta. 2014;1839:1217\u201325.","journal-title":"Biochim Biophys Acta"},{"key":"491_CR18","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.18632\/oncotarget.1831","volume":"5","author":"VK Kolukula","year":"2014","unstructured":"Kolukula VK, Sahu G, Wellstein A, Rodriguez OC, Preet A, Iacobazzi V, et al. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker. Oncotarget. 2014;5:1212\u201325.","journal-title":"Oncotarget"},{"key":"491_CR19","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.18632\/oncotarget.714","volume":"3","author":"O Catalina-Rodriguez","year":"2012","unstructured":"Catalina-Rodriguez O, Kolukula VK, Tomita Y, Preet A, Palmieri F, Wellstein A, et al. The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget. 2012;3:1220\u201335.","journal-title":"Oncotarget"},{"key":"491_CR20","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1073\/pnas.78.5.2861","volume":"78","author":"E Van Schaftingen","year":"1981","unstructured":"Van Schaftingen E, Hers HG. Inhibition of fructose-1,6-bisphosphatase by fructose 2,6-biphosphate. Proc Natl Acad Sci USA. 1981;78:2861\u20133.","journal-title":"Proc Natl Acad Sci USA"},{"key":"491_CR21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1124\/mol.109.058750","volume":"77","author":"S Aluvila","year":"2010","unstructured":"Aluvila S, Sun J, Harrison DH, Walters DE, Kaplan RS. Inhibitors of the mitochondrial citrate transport protein: validation of the role of substrate binding residues and discovery of the first purely competitive inhibitor. Mol Pharm. 2010;77:26\u201334.","journal-title":"Mol Pharm"},{"key":"491_CR22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbrc.2007.02.114","volume":"356","author":"V Infantino","year":"2007","unstructured":"Infantino V, Iacobazzi V, De Santis F, Mastrapasqua M, Palmieri F. Transcription of the mitochondrial citrate carrier gene: role of SREBP-1, upregulation by insulin and downregulation by PUFA. Biochem Biophys Res Commun. 2007;356:249\u201354.","journal-title":"Biochem Biophys Res Commun"},{"key":"491_CR23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3945\/an.113.004762","volume":"5","author":"A Ferramosca","year":"2014","unstructured":"Ferramosca A, Zara V. Dietary fat and hepatic lipogenesis: mitochondrial citrate carrier as a sensor of metabolic changes. Adv Nutr. 2014;5:217\u201325.","journal-title":"Adv Nutr"},{"key":"491_CR24","doi-asserted-by":"crossref","first-page":"e82364","DOI":"10.1371\/journal.pone.0082364","volume":"8","author":"T Brun","year":"2013","unstructured":"Brun T, Scarcia P, Li N, Gaudet P, Duhamel D, Palmieri F, et al. Changes in mitochondrial carriers exhibit stress-specific signatures in INS-1Ebeta-cells exposed to glucose versus fatty acids. PLoS ONE. 2013;8:e82364.","journal-title":"PLoS ONE"},{"key":"491_CR25","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.4161\/cc.22778","volume":"11","author":"OC Rodriguez","year":"2012","unstructured":"Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, et al. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle. 2012;11:4436\u201346.","journal-title":"Cell Cycle"},{"key":"491_CR26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","volume":"16","author":"K Kazankov","year":"2019","unstructured":"Kazankov K, Jorgensen SMD, Thomsen KL, Moller HJ, Vilstrup H, George J, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2019;16:145\u201359.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"491_CR27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jhep.2015.11.029","volume":"64","author":"S Mattu","year":"2016","unstructured":"Mattu S, Fornari F, Quagliata L, Perra A, Angioni MM, Petrelli A, et al. The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival. J Hepatol. 2016;64:891\u20138.","journal-title":"J Hepatol"},{"key":"491_CR28","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1038\/mtna.2014.4","volume":"3","author":"Y Hayashi","year":"2014","unstructured":"Hayashi Y, Suemitsu E, Kajimoto K, Sato Y, Akhter A, Sakurai Y, et al. Hepatic monoacylglycerol O-acyltransferase 1 as a promising therapeutic target for steatosis, obesity, and Type 2 diabetes. Mol Ther Nucleic Acids. 2014;3:e154.","journal-title":"Mol Ther Nucleic Acids"},{"key":"491_CR29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature17393","volume":"532","author":"L Jiang","year":"2016","unstructured":"Jiang L, Shestov AA, Swain P, Yang C, Parker SJ, Wang QA, et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature. 2016;532:255\u20138.","journal-title":"Nature"},{"key":"491_CR30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ymben.2016.11.004","volume":"43","author":"L Jiang","year":"2017","unstructured":"Jiang L, Boufersaoui A, Yang C, Ko B, Rakheja D, Guevara G, et al. Quantitative metabolic flux analysis reveals an unconventional pathway of fatty acid synthesis in cancer cells deficient for the mitochondrial citrate transport protein. Metab Eng. 2017;43:198\u2013207.","journal-title":"Metab Eng"},{"key":"491_CR31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fgene.2015.00204","volume":"6","author":"RP Rogers","year":"2015","unstructured":"Rogers RP, Rogina B. The role of INDY in metabolism, health and longevity. Front Genet. 2015;6:204.","journal-title":"Front Genet"},{"key":"491_CR32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature10163","volume":"474","author":"WC Skarnes","year":"2011","unstructured":"Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, et al. A conditional knockout resource for the genome-wide study of mouse gene function. Nature. 2011;474:337\u201342.","journal-title":"Nature"},{"key":"491_CR33","doi-asserted-by":"publisher","unstructured":"Toh TB, Lim JJ, Hooi L, Rashid M, Chow EK. Targeting Jak\/Stat pathway as a therapeutic strategy against SP\/CD44+ tumorigenic cells in Akt\/beta-catenin-driven hepatocellular carcinoma. J Hepatol. 2019. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.035.","DOI":"10.1016\/j.jhep.2019.08.035"},{"key":"491_CR34","doi-asserted-by":"crossref","first-page":"6750","DOI":"10.3748\/wjg.v23.i37.6750","volume":"23","author":"TN Flores-T\u00e9llez","year":"2017","unstructured":"Flores-T\u00e9llez TN, Villa-Trevi\u00f1o S, Pi\u00f1a-V\u00e1zquez C. Road to stemness in hepatocellular carcinoma. World J Gastroenterol. 2017;23:6750\u201376.","journal-title":"World J Gastroenterol"},{"key":"491_CR35","doi-asserted-by":"crossref","first-page":"8162421","DOI":"10.1155\/2017\/8162421","volume":"2017","author":"A Alisi","year":"2017","unstructured":"Alisi A, Carpino G, Oliveira FL, Panera N, Nobili V, Gaudio E. The role of tissue macrophage-mediated inflammation on NAFLD pathogenesis and its clinical implications. Mediators Inflamm. 2017;2017:8162421.","journal-title":"Mediators Inflamm"},{"key":"491_CR36","doi-asserted-by":"crossref","first-page":"18070","DOI":"10.3748\/wjg.v20.i48.18070","volume":"20","author":"S Stojsavljevi\u0107","year":"2014","unstructured":"Stojsavljevi\u0107 S, Gomer\u010di\u0107 Pal\u010di\u0107 M, Virovi\u0107 Juki\u0107 L, Smir\u010di\u0107 Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:18070\u201391.","journal-title":"World J Gastroenterol"},{"key":"491_CR37","doi-asserted-by":"crossref","first-page":"e0157956","DOI":"10.1371\/journal.pone.0157956","volume":"11","author":"AL Gavito","year":"2016","unstructured":"Gavito AL, Bautista D, Suarez J, Badran S, Arco R, Pav\u00f3n FJ, et al. Chronic IL-6 administration desensitizes IL-6 response in liver, causes hyperleptinemia and aggravates steatosis in diet-induced-obese mice. PLoS ONE. 2016;11:e0157956.","journal-title":"PLoS ONE"},{"key":"491_CR38","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1101\/gad.217406.113","volume":"27","author":"JA Losman","year":"2013","unstructured":"Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27:836\u201352.","journal-title":"Genes Dev"},{"key":"491_CR39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.trecan.2017.12.005","volume":"4","author":"D Ye","year":"2018","unstructured":"Ye D, Guan KL, Xiong Y. Metabolism, activity, and targeting of D- and L-2-hydroxyglutarates. Trends Cancer. 2018;4:151\u201365.","journal-title":"Trends Cancer"},{"key":"491_CR40","doi-asserted-by":"crossref","first-page":"dmm035337","DOI":"10.1242\/dmm.035337","volume":"11","author":"H Li","year":"2018","unstructured":"Li H, Hurlburt AJ, Tennessen JM. A Drosophila model of combined D-2- and L-2-hydroxyglutaric aciduria reveals a mechanism linking mitochondrial citrate export with oncometabolite accumulation. Dis Model Mech. 2018;11:dmm035337.","journal-title":"Dis Model Mech"},{"key":"491_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.10.003","volume":"185","author":"DM Willmes","year":"2018","unstructured":"Willmes DM, Kurzbach A, Henke C, Schumann T, Zahn G, Heifetz A, et al. The longevity gene INDY (I\u2019m Not Dead Yet) in metabolic control: potential as pharmacological target. Pharm Ther. 2018;185:1\u201311.","journal-title":"Pharm Ther"},{"key":"491_CR42","first-page":"101","volume":"2","author":"J Sun","year":"2010","unstructured":"Sun J, Aluvila S, Kotaria R, Mayor JA, Walters DE, Kaplan RS. Mitochondrial and plasma membrane citrate transporters: discovery of selective inhibitors and application to structure\/function analysis. Mol Cell Pharm. 2010;2:101\u201310.","journal-title":"Mol Cell Pharm"},{"key":"491_CR43","doi-asserted-by":"crossref","first-page":"3683026","DOI":"10.1155\/2018\/3683026","volume":"2018","author":"WA Poolsri","year":"2018","unstructured":"Poolsri WA, Phokrai P, Suwankulanan S, Phakdeeto N, Phunsomboon P, Pekthong D, et al. Combination of mitochondrial and plasma membrane citrate transporter inhibitors inhibits de novo lipogenesis pathway and triggers apoptosis in hepatocellular carcinoma cells. Biomed Res Int. 2018;2018:3683026.","journal-title":"Biomed Res Int"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41418-020-0491-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41418-020-0491-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41418-020-0491-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:15:29Z","timestamp":1684602929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-020-0491-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["491"],"URL":"https:\/\/doi.org\/10.1038\/s41418-020-0491-6","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,20]]},"assertion":[{"value":"8 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}